(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 March 2008 (13.03.2008)

PCT

(10) International Publication Number
WO 2008/030161 A1

(51) International Patent Classification:
A61K 31/4184 (2006.01)

(21) International Application Number:
PCT/SE2007/000771

(22) International Filing Date:
4 September 2007 (04.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/842,432 5 September 2006 (05.09.2006) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; S- 151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ABRAHAMSSON, Bertil** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **ÖDMAN, Jonas** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertalje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

WO 2008/030161 A1

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN CILEXETIL

(57) Abstract: A pharmaceutical composition comprising as an active ingredient candesartan or candesartan cilexetil, the composition exhibiting a relative bioavailability, measured as area under the curve, of more than 1.5.